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Abstract
Acute kidney injury (AKI) is a life-threatening condition and is especially 
dangerous in the vulnerable population of newborns. AKI is currently 
detected using the gold standard biomarker serum creatinine. Due to 
various disadvantages of creatinine when used in the neonatal 
population, it has been determined a suboptimal indicator of AKI. 
Cystatin C is a newly researched renal biomarker that is being considered 
for the assessment of neonatal kidney function. Therefore, this review 
analyzes the accuracy of Cystatin C (I) for detecting AKI (O) in preterm and 
term newborns (P) compared to the standard biomarker, creatinine (C). 
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Introduction
Methods
Literature Search
v Performed in November 2018 using:
§ Academic Search Premier with terms ”cystatin C AND neonates” 
§ PubMed with terms “cystatin C AND glomerular filtration rate”
v Searches were refined based on publication date after 2012, humans 
only, and newborn population
v Exclusion criteria: Systematic reviews, No free text access, or study 
focus not relevant to research question
v Inclusion criteria: newborn population and cystatin C use as focus
A total of seven studies were then chosen for this review 
All seven studies assessed serum and/or urine cystatin C levels 
and led to significant results suggesting they are both able to 
accurately estimate GFR and detect AKI in newborns.
Strengths
• The studies were able to validate that a neonate’s cystatin C 
levels are likely not affected by maternal levels, can accurately 
detect AKI, and reliably estimate GFR.
• All studies utilized a cohort study design, with the exception 
of one case-control study.
•No findings suggested cystatin C is inferior to creatinine
•All utilized clearly defined inclusion and exclusion criteria for 
determining the participants involved in the studies
Limitations
•Only one study utilized blinding technique
•Small sample sizes, especially in AKI groups
•Use of varying GFR equations
Discussion Results 
The Accuracy of Cystatin C in the 
Detection of Kidney Injury in Newborns
The study results suggest that cystatin C  is an accurate indicator
of kidney function and can reliably detect AKI in the neonatal 
population. Although characteristics of cystatin C are found to 
be superior to creatinine in the neonatal population, it is still not 
readily accessible in healthcare. One barrier to the use of this 
biomarker in clinical practice is the expensive cost. 
Future studies are needed to assess the gaps in current research 
including: correlation between serum cystatin C and gestational 
age, the interaction between cystatin C and other underlying 
health conditions, and the timing between a rise in cystatin C 
before AKI development. 
Overall, the results are promising, but additional research is 
needed before there is a change in the gold standard.
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Study Design Total 
N
Population Demographics Length of 
Study 
Timing of Diagnostic Measures Diagnostic 
measurements
Abitbol et al 
(2014)
Cross sectional 
Cohort
100 60: preterm
40: full term
1 week sCr and sCysC levels were determined 
48 hours after birth and within the first 
week of life
sCysC, sCr, total 
kidney volume, 
GFR
Elmas et al 
(2013)
Prospective 
case-control 
study 
62 All preterm neonates 
28: RDS (6 with AKI)
34: no RDS (control)
30 days Each neonate had peripheral blood 
samples drawn on postnatal day 3 and 
day 30
BUN, sCysC, sCr
Treiber et al 
(2015)
Cross sectional-
Cohort
100 50 SGA full-term neonates
50 AGA full-term neonates
3 days Blood samples taken from the umbilical 
cord at birth and then from peripheral 
veins on day 3 of life
sCysC, sCr, total 
kidney volume, 
GFR
Li et al 
(2012) 
Cohort 62 All were considered non-septic 
critically ill neonates
11 fulfilled AKI criteria
10 days Urine samples were collected every 48-
72 hours within first 10 days of 
neonates’ lives
uCysC, uIL-18, uCr
Lee et al 
(2013)
Cohort 246 127: premature
119: full term
First 30 
postnatal 
days
Blood samples obtained during first 30 
postnatal days when routine blood 
screening tests performed 
sCysC, sCr
DeFrietas et 
al (2016)
Cohort 52 39: preterm 
13: full-term 
First 3 
months 
of life
Urine samples obtained in first days of 
life and at 3 months postnatal 
sCr sample drawn in first week of life 
after 24-hour period
sCr, GFR, uCysC, 
uALB, uB2M, 
uEGF, uNGAL, 
uOPN, uUMOD
Kasamatsu et 
al (2016)
Retrospective 
Cohort
87 Preterm and full-term neonates
38: transient tachypnea
First 24 
hours of 
life
Maternal sCr and sCysC levels were 
measured within 48 h before delivery
Neonates’ sCr and sCysC levels were 
measured at the time of birth
sCysC, sCr, urine 
volume
Key: 
Preterm: <37 weeks’ gestational age; Full term: >37 weeks’ gestational age; sCysC: serum cystatin C; sCr: serum creatinine; GFR: glomerular filtration rate; 
uCysC: urinary cystatin C; uALB: albumin; uB2M: beta-2-microglobulin; uEGF: epidermal growth factor; uNGAL: neutrophil-gelatinase-associated lipcalin, 
uOPN: osteopontin; uUMOD: uromodulin; RDS: respiratory distress syndrome; SGA: small for gestational age; AGA: appropriate weights for gestational age
The diagnosis of AKI is currently based on a rise in serum creatinine and/or 
a decrease in urine output. Glomerular filtration rate (GFR)  is used to 
measure kidney function and detect AKI. GFR is estimated using equations 
based on renal biomarkers, most commonly this is creatinine. 
Creatinine (Cr)
• Formed from creatine in muscle and normally cleared by renal excretion
• Limitations include:
ØDelay of 48-72 hours before rise of serum Cr
ØAbout 25-50% loss of kidney function before serum Cr increase
ØCrosses the placenta barrier causing first day neonate Cr levels to 
reflect mother’s renal function instead
ØVaries based on muscle mass, hydration, gestational age, & birthweight. 
Cystatin C (CysC)
• Cysteine proteinase inhibitor that is produced at a constant rate by cells
• Entirely eliminated by kidney’s glomerular filtration system 
• Does not cross placenta.
Table 1. Comparison of Study Designs
